A new upload by YRH--- "Non small cell lung cancer therapeutics in major developed markets to 2021 - emergence of immunotherapies drives market growth and creates a competitive second-line"

1. Get Full report with Table of Contents:
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
YRH: Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets
to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates
A Competitive Second-Line
Overview, Size, Share, Analysis, Technology Developments, Development
Status, Trends, Structure, Production Value and Forecast Research Report
Get Full Report with Table of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to
2021 - Emergence of Immunotherapies Drives Market Growth and Creates A
Competitive Second-Line
Summary:
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
Summary
Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most
common cause of cancer-related mortality. Such a poor outlook, particularly for patients with
advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market
is undergoing a gradual change from a focus on generic chemotherapy regimens to complex
treatment landscape based on different NSCLC subtypes and the presence of various molecular
aberrations. In the current market, patients with non-squamous histology can be treated with more
efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in
EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim
to improve the outlook for all patients, there is currently a lack of options for patients with
squamous cell histology or other detectable molecular characteristics besides EFGR and ALK
mutations.
Scope
The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR
of 8.5% -
- How will immunotherapies such as Keytruda affect growth?
- What effect will patent expirations of Tarceva and Alimta have on market value?

2. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted
therapies in contrast to the market -
- What are the common targets and mechanisms of action of pipeline therapies?
- Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
- What implications will the increased focus on targeted therapies have on the future of NSCLC
treatment?
Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the
market over the forecast period -
- How have promising late-stage therapies performed in clinical trials?
- How would the approval of Rociletinib affect the competitive landscape?
- What is the individual commercial forecast for each therapy?
The market forecasts indicate that the US contributes the most to global market value due to a large
treatment population and the high price of premium therapies.
- How will ACoT and market size vary between the eight major markets?
- How could a change in risk factors such as population age or smoking habits influence the market?
Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values
ranging from under $10m to over $1 billion.
- How do deal frequency and value compare between target families and molecule types?
- What were the terms and conditions of key licensing deals?
Reasons to buy
This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis,
diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a
clinical comparison of marketed therapies.
- Visualize the composition of the NSCLC market in terms of dominant therapies for each patient
subset along with their clinical and commercial standing. Unmet needs in the current market are
highlighted to allow a competitive understanding of gaps in the current market.
- Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type
and molecular target.

3. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
- Understand the potential of late-stage therapies with extensive profiles of products that could
enter the market over the forecast, highlighting clinical performance, potential commercial
positioning, and how they will compete with other therapies.
- Predict NSCLC market growth in eight major markets with epidemiological and ACoT forecasts
across the US, Canada, UK, France, Germany, Italy, Spain and Japan, as well as individual drug
contributions to market growth.
- Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and
co-development deals.
Get Full Report with Table of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Introduction 8
2.2 Epidemiology 9
2.3 Etiology and Pathophysiology 9
2.3.1 Adenocarcinoma 11
2.3.2 Squamous Cell Carcinoma 13
2.3.3 Large Cell Carcinoma 15
2.3.4 Immunotherapy 16
2.4 Symptoms 17
2.5 Diagnosis 17
2.6 Prognosis 19
2.7 Treatment 20
2.7.1 Treatment Algorithm 21
2.7.2 First-Line Treatment 21
2.7.3 Maintenance Therapy 23
2.7.4 Second-Line Treatment 24
2.7.5 Third-Line Therapy 25
2.7.6 Adjuvant Therapy 25
2.8 Marketed Product Heatmaps 25
3 Marketed Products 29
3.1 Overview 29
3.2 Chemotherapies 29
3.3 Alimta - Eli Lilly 29
3.4 Abraxane - Celgene Corporation 30
3.5 Tarceva - Roche 31
3.6 Iressa - AstraZeneca 32

4. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
3.7 Gilotrif - Boehringer Ingelheim 33
3.8 Xalkori - Pfizer 34
3.9 Avastin - Roche 34
3.10 Cyramza - Eli Lilly 35
3.11 Opdivo - Bristol-Myers Squibb 36
3.12 Zykadia - Novartis 37
3.13 Alectinib - Roche 38
3.14 Conclusion 39
4 NSCLC Pipeline 40
4.1 Overview 40
4.2 Mechanisms of Action and Targets in the Pipeline 43
4.3 Clinical Trials 45
4.3.1 Failure rate 45
4.3.2 Clinical Trial Duration 48
4.3.3 Clinical Trial Size 50
4.3.4 Clinical Trial Summary 55
4.4 Late-Stage Pipeline Product Profiles 56
4.4.1 Ganetespib - Synta Pharmaceuticals 56
4.4.2 Yervoy - Bristol-Myers Squibb 57
4.4.3 Custirsen - Oncogenex Pharmaceuticals 59
4.4.4 Atezolizumab - Roche 60
4.4.5 Necitumumab - Eli Lilly 62
4.4.6 Patritumab - Daiichi Sankyo 63
4.4.7 Selumetinib - AstraZeneca 64
4.4.8 Rociletinib - Clovis Oncology 65
4.4.9 AZD-9291 - AstraZeneca 67
4.4.10 Vaxira - Recombio 68
4.4.11 Keytruda - Merck 70
4.4.12 TG4010 - Transgene 71
4.4.13 Veliparib - AbbVie 72
4.4.14 Abemaciclib - Eli Lilly 73
4.4.15 Bavituximab - Peregrine Pharmaceuticals 75
4.5 Pipeline Heatmaps and Product Competitiveness 76
4.5.1 Product Competitiveness Framework 79
4.6 Pipeline Conclusion 80
5 Market Forecast 81
5.1 Geographical Markets 81
5.1.1 Global Markets 82
5.1.2 North America 83
5.1.3 Top Five EU Countries 86
5.1.4 Japan 91
5.2 Drivers and Barriers 93
5.2.1 Drivers 93
5.2.2 Barriers 93
6 Strategic Consolidations 95
6.1 Major Licensing Deals 95

5. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
6.1.1 Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 98
6.1.2 Novartis Enters into Licensing Agreement with Antisoma 98
6.1.3 Ariad Pharma Enters into a Collaboration Agreement with Merck 99
6.1.4 Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib 99
6.2 Major Co-Development Deals 99
6.2.1 Pfizer Enters into Co-Development Agreement with Merck 102
6.2.2 Merck Enters into Co-Development Agreement with Endocyte 102
6.2.3 GlobeImmune Enters into Agreement with Celgene 103
6.2.4 Amgen Enters into Co-Development Agreement with Takeda Pharmaceutical 103
7 Appendix 104
7.1 References 104
7.2 Abbreviations 108
7.3 Research Methodology 109
7.3.1 Secondary Research 110
7.3.2 Marketed Product Profiles 110
7.3.3 Late-Stage Pipeline Candidates 110
7.3.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 111
7.3.5 Product Competitiveness Framework 111
7.3.6 Pipeline Analysis 111
7.3.7 Forecasting Model 112
7.3.8 Deals Data Analysis 113
7.4 Expert Panel Validation 113
7.5 Contact Us 113
7.6 Disclaimer 113
Get Full Report with Table of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
Table of Figures:
1.1 List of Tables
Table 1: NSCLC, Tumor Node Metastasis Classification, 2015 18
Table 2: NSCLC, Eastern Co-operative Oncology Group Criteria, 2015 19
Table 3: NSCLC, Treatment Options, 2015 21
Get Full Report with Table of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
About Us:

6. www.YourResearchHub.com
Get Full Report With Table Of Contents at
Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of
Immunotherapies Drives Market Growth and Creates A Competitive Second-Line
yourresearchhub Not sure if a research on a topic has ever been conducted? Will an existing
research report go in enough detail? Is the report right for me? Have doubts ?
We’re here to help you.
We at Research Hub, are in the field of connected marketing built by a team of highly
qualified professionals with collective knowledge and expertise in both technology as well as
global marketing.
We bring industry research reports from carefully chosen analysts and publishers across the
globe under a single offering to help our clients with quality research and analysis leading to
actionable insight.
A significant portion of our business is organically sourced and this is where we stand out of
the crowd. Our customers come across us mostly while looking for market insights at
avenues where they are looking for genuine advice. We connect with our clients and
actively participate in shaping their research needs – which as a result guaranties a
product that they are sure will benefit them.
Our partners connect with us for the same reasons that our clients conduct their business
with us – the unique model of offering our marketing services. We work very closely with
our partners and bring their strengths to the market in a very effective manner.
Our teams are collocated in India and the UK to provide an unmatched quality of service.
Feel free to contact us at queries@YourResearchHub.Com should you have any questions or
suggestions.
For More Information –
Please call us or write to us:
UK: +44 208123 7101
Email: sales@yourresearchhub.com
Follow Us –
Browse Blog at http://www.yourresearchhub.com/blogs/news